| | |
C.H. Unnikrishnan 08:41 PM | November 12,2009
In the past half a decade, big pharmaceutical firms haven’t developed any new blockbuster drugs, the lifeblood for them
|
|
C.H. Unnikrishnan and Reuters 10:56 PM | November 11,2009
The drug maker has offered to supply its A/H1N1 influenza drug, to the US
|
|
Reuters 04:01 PM | November 11,2009
Patents protection for Roche’s Tamiflu in US and Europe has not allowed Cipla to sell its generic version in these two geographies, its chairman Y K Hamied said
|
|
Sumeet Chatterjee / Reuters 10:54 AM | November 11,2009
Analysts say growth in the sector will also be boosted by the biggest loss of patent protection in history in the next couple of years
|
|
C.H. Unnikrishnan 10:39 PM | November 03,2009
The industry will be paid for the performance of the product and not just for the product, Friend says
|
|
C.H. Unnikrishnan 11:39 PM | October 30,2009
The company’s sales during the period grew 12% at Rs522.68 crore compared with Rs478.84 crore
|
|
C.H. Unnikrishan 12:08 AM | October 30,2009
Sales grew 4.6% from the year-ago period to Rs161.5 crore
|
|
Mark to Market | Manas Chakravarty, Mobis Philipose, Ravi Ananthanarayanan and Vatsala Kamat 10:21 PM | October 29,2009
Glenmark raised around Rs400 crore through an equity issue in September, which has been used to reduce debt
|
|
Archi Damania / CNBC-TV18 12:53 AM | October 29,2009
Cipla chairman and managing director Y.K. Hamied said a lot of the growth has been in the anti-AIDS drugs
|
|
Mark to Market | Mobis Philipose and Vatsala Kamat 01:02 AM | October 27,2009
The fall in sales was mainly the result of an all-round dip across developed markets
|
|
Radhieka Pandeya 09:12 PM | October 26,2009
The company has registered a profit despite a 53% decline in sales in the US and a 25% drop in Romania
|
|
Mark to Market | Mobis Philipose, Vatsala Kamat and Ravi Ananthanarayanan 11:02 PM | October 25,2009
Profit from operating activities grew by 44% to Rs254 crore, and aided by higher interest income, net profit more than doubled to Rs217 crore
|
|
Mark to Market | Mobis Philipose, Ravi Ananthanarayanan and Vatsala Kamat 12:59 AM | October 23,2009
Biocon is evidently on a steady track. But whether it makes it to the big league will depend on success in research in the next year or two
|
|
Reuters 07:00 PM | October 13,2009
Its net earnings rose 1.1% to $3.35 billion from $3.31 billion a year earlier
|
|
Reuters 09:02 AM | October 08,2009
IMS said higher-than-anticipated demand caught pharmacies off guard, forcing them to rebuild inventories slashed late last year as they girded for the impact of a deep recession
|
|